LT3319963T - Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas - Google Patents

Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas

Info

Publication number
LT3319963T
LT3319963T LTEP16741469.7T LT16741469T LT3319963T LT 3319963 T LT3319963 T LT 3319963T LT 16741469 T LT16741469 T LT 16741469T LT 3319963 T LT3319963 T LT 3319963T
Authority
LT
Lithuania
Prior art keywords
azaindols
substituted
receptor modulators
glun2b receptor
glun2b
Prior art date
Application number
LTEP16741469.7T
Other languages
English (en)
Inventor
Christa C. Chrovian
Michael A. Letavic
Jason C. Rech
Akinola Soyode-Johnson
Jessica L. WALL
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LT3319963T publication Critical patent/LT3319963T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
LTEP16741469.7T 2015-07-09 2016-07-07 Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas LT3319963T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
LT3319963T true LT3319963T (lt) 2020-03-25

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16741469.7T LT3319963T (lt) 2015-07-09 2016-07-07 Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas

Country Status (25)

Country Link
US (2) US9963447B2 (lt)
EP (1) EP3319963B1 (lt)
JP (2) JP6964576B2 (lt)
KR (1) KR20180026760A (lt)
CN (1) CN108026094B (lt)
AU (1) AU2016291158B2 (lt)
BR (1) BR112018000468A2 (lt)
CA (1) CA2991765C (lt)
CY (1) CY1123007T1 (lt)
DK (1) DK3319963T3 (lt)
EA (1) EA033197B1 (lt)
ES (1) ES2781867T3 (lt)
HR (1) HRP20200410T1 (lt)
HU (1) HUE047460T2 (lt)
IL (1) IL256758A (lt)
LT (1) LT3319963T (lt)
MA (1) MA42397B1 (lt)
MD (1) MD3319963T2 (lt)
MX (1) MX2018000352A (lt)
PL (1) PL3319963T3 (lt)
PT (1) PT3319963T (lt)
SI (1) SI3319963T1 (lt)
SM (1) SMT202000134T1 (lt)
WO (1) WO2017007938A1 (lt)
ZA (1) ZA201800827B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CN113993868A (zh) * 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
KR20220024403A (ko) * 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
CN113950357A (zh) 2019-06-14 2022-01-18 詹森药业有限公司 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
SG11202112405VA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
JP7667097B2 (ja) * 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
CN114621125B (zh) * 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490364B1 (en) * 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物
US20100325949A1 (en) 2007-07-03 2010-12-30 Edward Scott Carlson Support apparatus for climbing plants
CN101842357A (zh) 2007-08-30 2010-09-22 武田药品工业株式会社 取代的吡唑衍生物
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
WO2009118187A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
RU2517181C2 (ru) * 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
SG11201506687RA (en) * 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途

Also Published As

Publication number Publication date
CA2991765C (en) 2023-10-03
JP2018520170A (ja) 2018-07-26
IL256758A (en) 2018-03-29
CA2991765A1 (en) 2017-01-12
SMT202000134T1 (it) 2020-05-08
ZA201800827B (en) 2019-09-25
HK1255160A1 (en) 2019-08-09
DK3319963T3 (da) 2020-02-03
US9963447B2 (en) 2018-05-08
BR112018000468A2 (pt) 2018-09-18
CY1123007T1 (el) 2021-10-29
WO2017007938A1 (en) 2017-01-12
CN108026094B (zh) 2021-02-09
US20170008890A1 (en) 2017-01-12
AU2016291158B2 (en) 2020-04-30
EP3319963A1 (en) 2018-05-16
KR20180026760A (ko) 2018-03-13
PL3319963T3 (pl) 2020-06-01
JP6964576B2 (ja) 2021-11-10
ES2781867T3 (es) 2020-09-08
CN108026094A (zh) 2018-05-11
US20180208595A1 (en) 2018-07-26
MX2018000352A (es) 2018-08-15
MD3319963T2 (ro) 2020-05-31
MA42397B1 (fr) 2020-02-28
EA201890245A1 (ru) 2018-06-29
HUE047460T2 (hu) 2020-04-28
EP3319963B1 (en) 2020-01-08
SI3319963T1 (sl) 2020-02-28
US10377753B2 (en) 2019-08-13
AU2016291158A1 (en) 2018-02-01
JP7369743B2 (ja) 2023-10-26
PT3319963T (pt) 2020-04-09
JP2021193099A (ja) 2021-12-23
EA033197B1 (ru) 2019-09-30
HRP20200410T1 (hr) 2020-08-21

Similar Documents

Publication Publication Date Title
MA43382A (fr) Modulateurs des récepteurs des chimiokines
LT3319963T (lt) Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
IL258359A (en) Farnesoid x receptor modulators
HRP20260361T1 (hr) Supstituirani 4-fenilpiperidini, njihova priprava i uporaba
LT3363438T (lt) Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių
HUE053943T2 (hu) Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
LT3169307T (lt) Vandeninė kompozicija, apimanti paracetamolį ir ibuprofeną
PT3212237T (pt) Formulação de metotrexato
LT3337506T (lt) Deriniai ir jų panaudojimas
HRP20200170T1 (hr) Celobioza fosforilaza
DE112015003404A5 (de) Dämpfersystem
BR112016025075A2 (pt) formulação agroquímica.
BR112016027580A2 (pt) Formulação de ceritinib
DE112015001610A5 (de) Dämpfersystem
IL249897B (en) 2-oxo-4,3-dihydropyridine-5-carboxylates and their use
BR302014001542S1 (pt) Configuração aplicada em calota
BR302014001539S1 (pt) Configuração aplicada em calota
BR302014000405S1 (pt) Configuração aplicada em calota
BR302014000606S1 (pt) Configuração aplicada em touca
BR302014002719S1 (pt) Configuração aplicada em cadeira
BR302014001694S1 (pt) Configuração aplicada em cadeira ou similar
BR302014002222S1 (pt) Configuração aplicada em cadeira
BR302014002054S1 (pt) Configuração aplicada em cadeira